Byetta Amylin Pharmaceuticals / Eli Lilly & Co. - Treatment for Type 2 Diabetes
Byetta is the first in a new class of drugs called incretin mimetics, formulated for self-administration as a fixed dose, subcutaneous injection given prior to the morning and evening meals. Byetta is indicated as as adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on metformin and/or a sulfonylurea, two common oral diabetes medications.Posted: April 2005
Related articles
- Byetta Approved for Use with Insulin Glargine in the U.S. - October 20, 2011
- Byetta Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes - November 2, 2009
- Exenatide New Drug Application Accepted for Review by the FDA - September 1, 2004
- New Drug Application for Exenatide Submitted to FDA for Type 2 Diabetes - June 30, 2004
Byetta (exenatide) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
